The company shows excellent top-line and bottom-line growth. Compounded sales growth is strong at 32% (5Y) and 23% (3Y). Similarly, compounded profit growth is outstanding at 79% (5Y) and 54% (3Y). Operating profit margins are on an improving trajectory, rising from 2% in FY22 to a projected 8% in FY26. This indicates an ability to scale operations profitably. However, financial performance shows volatility in quarterly net profits, which fluctuated significantly in recent periods (e.g., from 12 Cr in Mar 2024 to a projected 6 Cr in Jun 2024), pointing to potential instability in earnings.

While Return on Capital Employed (14% in FY24) is at an acceptable level, the underlying efficiency metrics show a significant deterioration. The Cash Conversion Cycle has expanded dramatically from 26 days in FY22 to a projected 186 days in FY26, indicating severe issues in managing working capital. This is further corroborated by the rising Debtor Days (from 11 to 49) and Inventory Days (from 31 to 181) over the same period. Additionally, the Asset Turnover ratio is declining, falling from 4.24 in FY22 to a projected 1.30 in FY26. This suggests that the company is becoming less effective at using its assets to generate sales.

The company's financial health is a major concern. Borrowings have been increasing rapidly, from 47 Cr in FY22 to a projected 236 Cr in FY26. While the debt-to-equity ratio remains manageable, its upward trend is concerning. The most critical issue is the consistently negative Cash from Operating Activities, which was -61 Cr in FY23 and -10 Cr in FY24, with projections indicating further negative flows. This signifies that the company's core operations are consuming cash. Consequently, the Interest Coverage Ratio has declined sharply from 6.14x in FY22 to 2.81x in FY24, indicating a reduced capacity to service its growing debt obligations.

Promoter holding is high and has shown a slight increase over the years, standing at a projected 66.50% as of March 2026. This indicates strong promoter confidence and alignment of interests with minority shareholders. However, a significant concern is the near-total absence of institutional investors. Both Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) hold negligible stakes in the company (0.01% and 0.00% respectively as of March 2026). This lack of institutional participation suggests that sophisticated investors may be wary of the company's financial health and governance, despite its high growth and strong promoter backing.

Several accounting quality red flags are present. The most significant is the divergence between reported profit and cash flow. The company has reported consistently negative Cash from Operating Activities (-61 Cr in FY23, -10 Cr in FY24) despite showing strong profit growth. The CFO/Operating Profit ratio is alarmingly negative (-321% in FY23, -26% in FY24), indicating that profits are not being converted into cash. This is driven by a ballooning of working capital. Additionally, the company reported negative tax percentages in its P&L for FY23 (-12%) and FY24 (-12%), which is unusual and warrants scrutiny.

The company faces significant risk from interest rate fluctuations. Total borrowings have increased from 47 Cr in FY22 to a projected 236 Cr in FY26. Correspondingly, interest expenses have escalated sharply, from 2 Cr in FY22 to a projected 37 Cr in FY26. This rapid accumulation of debt has weakened the company's ability to service its interest obligations. The Interest Coverage Ratio has deteriorated from 6.14x in FY22 to a much lower 2.81x in FY24 and is projected to remain low. This indicates a reduced buffer to absorb any further increases in interest rates or a downturn in operating profit.